Form 4: Emergent BioSolutions Executive Acquires Stock Options
SEC Filing Form 4
Coleen Glessner, EVP at Emergent BioSolutions, reports acquisition of employee stock options.
Summary
- Coleen Glessner, an Executive Vice President at Emergent BioSolutions, filed a Form 4 indicating changes in beneficial ownership.
- The report details the acquisition of 125,000 employee stock options on March 13, 2024, at an exercise price of $2.33.
- These options vest in three equal installments beginning on March 12, 2031.
- Following the transaction, Glessner directly owns 187,113 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports a transaction without expressing any positive or negative outlook.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by an executive can be viewed positively by shareholders as it aligns management's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of transaction: acquisition of employee stock options. |
| 03/12/2031 | Options vest in three equal installments beginning on this date. |
| 03/15/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.